ArticleUrology research & practice2025
Revisiting Skull Metastases of Prostate Cancer at Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography Era: PSMA Uptake Characteristics and Oncological Outcomes.
Article in Urology research & practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We aimed to evaluate prostate-specific membrane antigen (PSMA) uptake characteristics and the oncological outcomes in patients with skull metastases. Methods: The records of 345 serial PSMA positron emission tomography (PET)/computed tomography (CT) scans of 96 patients with metastatic prostate cancer (PCa) were evaluated retrospectively. Skull bone metastasis was detected in 18 patients (18/96, 18.7%), with a mean age of 72.4 ± 9.1 years, and in 40 PSMA PET/CT scans (40/345, 11.6%). Involved skull bones, PSMA uptake characteristics, and CT counterparts of metastatic lesions were centrally reviewed. Prostate specific antigen (PSA) levels at the time of skull metastasis detection and PSMA-detected other metastatic lesions were recorded. Results: All patients with a skull metastasis showed multiple other metastatic bone lesions, and 6 (33.3%) had visceral metastasis. Seven (38.9%) patients had solitary skull lesions, whereas 11 (61.1%) had multiple skull metastases. Twenty-two out of 37 (59.5%) metastatic lesions had no CT counterpart. The median SUVmax was significantly higher in metastatic lesions with a CT counterpart (median 9.09 vs. 4.63, P = .018). At a median follow-up of 23.4 mo (interquartile range [IQR] 8.7-34.1) after detection of skull metastasis, 5 out of 11 (45.5%) hormone-sensitive and all castration-resistant patients died of PCa. The median survival of patients with castration-resistant disease was 9.92 months. Conclusion: The majority of PSMA-detected skull metastases did not show a CT counterpart, which may explain why skull metastases were rarely detected before the PSMA PET-era. In high-volume metastatic prostatic cancer cases, 68Ga-PSMA PET/CT imaging field including the vertex, may enhance the accuracy in detecting tumor extent and metabolic tumor volume.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.